Therapeutic effectiveness of COVID-19 convalescent plasma produced by HEMOPE: a multicenter, randomized and controlled clinical trial - PLAVID-TRIAL: Covid convalescent plasma - Clinical Trial

niversidade de Pernambuco0 sitesJune 29, 2020

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Not specified
Sponsor: niversidade de Pernambuco
Status: Not yet recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

June 29, 2020

End Date

TBD

Last Updated

2 years ago

Study Type

Intervention

Investigators

Sponsor

niversidade de Pernambuco

Eligibility Criteria

Inclusion Criteria

•adults\> 18 years with diagnosis of COVID – 19, who are hospitalized; and considered as having a condition that increases the risk of a worse prognosis: obesity; diabetes mellitus (DM); systemic arterial hypertension (SAH); chronic lung disease, obesity, diseases that alter immunity (AIDS, neoplasms or autoimmune diseases in immunosuppressive therapy, chronic liver disease.

Exclusion Criteria

•History of anaphylactic reaction related to blood transfusion.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting

Phase 1

Cure COVID: A study to compare the efficacy of GNS561 versus standard treatments in patients with SARS-CoV-2 (COVID-19) infection.COVID-19 infectionMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]

EUCTR2020-002249-40-BGGenoscience Pharma120

Recruiting

Phase 3

Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this diseaseCOVID-19.COVID-19, virus identifiedU07.1

IRCT20151228025732N53Semnan University of Medical Sciences12

Suspended

Phase 2

Convalescent Antibody-Mediated Treatment of COVID-19 Infections in Patients with B-cell dysfunction, a Randomized Trial (COVID-Compromise Study).

NL-OMON51203Academisch Medisch Centrum86

Recruiting

Not Applicable

COVID-Compromise

NL-OMON25136AmsterdamUMC86

Active, not recruiting

Phase 1

An infusion of antibodies to COVID-19 for patients with B cell disorder, a randomized (randomized) study (COVID Compromise study).COVID-19 disease due to an infection with SARS-CoV2-virusTherapeutic area: Diseases [C] - Virus Diseases [C02]

EUCTR2020-006075-15-NLAmsterdam UMC86